BREAKING: Target Test Prep releases Brand New 2026 On Demand GMAT prep course

Redeem

Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

★★★★★5.0559 reviews
Vote for Target Test Prep, Newsweek Readers’ Choice Awards 2026
NEWSWEEK READERS’ CHOICE 2026

BIG NEWS! Target Test Prep has been nominated, and they’d love your vote!

TTP has worked incredibly hard to build the best test prep experience possible, and winning Newsweek’s 2026 Readers’ Choice Award for Best Test Prep would mean a lot to them. If TTP has helped you, they’d be incredibly grateful for your vote. You can vote once each day through September 9.

Vote for TTP
GMATLiveTeach 7 seats left
Chris Peckover
NEXT LIVE COHORT

Oct 13 to Jan 7, 2027

with Chris Peckover

Schedule
Tue, Thu · 8:00 to 10:00 PM ET
Included
40 live hours + 6 months of GMAT OnDemand
  • Live instruction and real-time questions
  • Class recordings and assigned practice
View class & enroll
Limited cohort · enrollment openTarget Test Prep
EALiveTeach 5 seats left
Logan Thompson
EXECUTIVE ASSESSMENT

Sep 6 to Dec 6, 2026

with Logan Thompson

Schedule
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll
Limited cohort · enrollment openTarget Test Prep
GMATOnDemand Start anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions

Compare the format, schedule, and included access before enrolling. Prices and seat counts shown reflect the supplied offer details.

Two investigative journalists have raised the question whether the new blood pressure drug, Transerythropaxil, has

Expert replies
by BTGmoderatorDC » Mon Nov 28, 2022 12:13 am

Timer

00:00

Answers

A

B

C

D

E

Stats

Difficulty

Two investigative journalists have raised the question whether the new blood pressure drug, Transerythropaxil, has sensitized patients to develop fish allergies. The study was published last month in a major newspaper, and has been picked up by media throughout the country. Lab data has long shown that Transerythropaxil reacts strongly with Eicosapentaenoic acid, found in abundance in fish oil, and this reaction can produce biological irritants. Despite strenuous objections from Transerythropaxil's manufacturer, scientists working in federal labs have just published papers that provide conclusive evidence to the journalists' claim.

In the argument given, the two portions in boldface play which of the following roles?


(A) The first states the conclusion of the argument; the second calls that conclusion into question.

(B) The first provides support for conclusion of the argument; the second calls that conclusion into question.

(C) The first provides support for conclusion of the argument; the second identifies the content of that conclusion

(D) The first identifies the content of the conclusion of the argument; the second provides support for that conclusion.

(E) Each provides support for the conclusion of the argument


OA D

Source: Magoosh
Join the discussion
Source: — Critical Reasoning |